siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses
Authors:
- 4 May 2021
- journal article
- review article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 18 (6) , 2105-2121
Abstract
The ongoing pandemic of global concern has killed about three million humans and affected around 151 million people worldwide, as of April 30, 2021. Although recently approved vaccines for COVID-19 are engendering hope, finding new ways to cure the viral pandemic is still a quest for researchers worldwide. Major pandemics in history have been of viral origin, such as SARS, MERS, H1NI, Spanish flu, and so on. A larger emphasis has been on discovering potential vaccines, novel antiviral drugs, and agents that can mitigate the viral infection symptoms; however, a relatively new area, RNA interference (RNAi), has proven effective as an antiviral agent. The RNAi phenomenon has been largely exploited to cure cancer, neurodegenerative diseases, and some rare diseases. The U.S. Food and Drug Administration has recently approved three siRNA products for human use that garner significant hope in siRNA therapeutics for coronaviruses. There have been some commentaries and communications addressing this area. We have summarized and illustrated the significance and the potential of the siRNA therapeutics available as of April 30, 2021 to combat the ongoing viral pandemic and the emerging new variants such as B.1.1.7 and B.1.351. Numerous successful in vitro studies and several investigations to address the clinical application of siRNA therapeutics provide great hope in this field. This seminal Review describes the significance of siRNA-based therapy to treat diverse viral infections in addition to the current coronavirus challenge. In addition, we have thoroughly reviewed the patents approved for coronaviruses, the major challenges in siRNA therapy, and the potential approaches to address them, followed by innovation and prospects.Keywords
Funding Information
- School of Pharmacy, Chapman University
This publication has 140 references indexed in Scilit:
- 5′ Unlocked Nucleic Acid Modification Improves siRNA TargetingMolecular Therapy Nucleic Acids, 2013
- Recent Progress in Studies of Arterivirus- and Coronavirus-Host InteractionsViruses, 2012
- Delivery of siRNA Therapeutics: Barriers and CarriersThe AAPS Journal, 2010
- Identification of In Vivo-Interacting Domains of the Murine Coronavirus Nucleocapsid ProteinJournal of Virology, 2009
- A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicityNucleic Acids Research, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Cathepsin L Functionally Cleaves the Severe Acute Respiratory Syndrome Coronavirus Class I Fusion Protein Upstream of Rather than Adjacent to the Fusion PeptideJournal of Virology, 2008
- Conformational States of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein EctodomainJournal of Virology, 2006
- Interfering with hepatitis C virus RNA replicationVirus Research, 2004
- Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysateThe EMBO Journal, 2001